Professional
Added to YB: 2026-09-21
Pitch date: 2026-09-15
AGEN [bearish]
Agenus Inc.
-8.28%
current return
Author Info
Shortfinder specializes in in uncovering small-cap companies at risk of dilution, regulatory setbacks, or fundamental weaknesses. Sign up for the newsletter.
Company Info
Agenus Inc., a clinical-stage biotechnology company, discovers and develops immunotherapies for cancer and infectious diseases in the United States and internationally.
Market Cap
$353.4M
Pitch Price
$7.25
Price Target
5.20 (-34%)
Dividend
N/A
EV/EBITDA
7.38
P/E
3.13
EV/Sales
2.78
Sector
Biotechnology
Category
special_situation
Shortfinder Research: Agenus (AGEN): The PIPE Is Up 93% and Every Share of It Is Registered
AGEN (short): The thesis is supply, not drug failure: short Agenus at $7.13 with a $5.20 target over 30–90 days. All 78.0M shares and underlying shares from July’s $3.69 PIPE are registered and in the money versus a 30.7M-share float, while warrant exercise is needed to extend cash beyond Q3 2027. Use a half position and $8.60 stop given 21.8% short interest and partnership or clinical-update risk.
Read full article (15 min)